Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
>
Chemicals & Drugs
>
Amino Acid
>
Bevacizumab
Bevacizumab
Bevacizumab is a recombinant humanized monoclonal antibody that binds to and inhibits the vascular endothelial growth factor (VEGF), a key regulator of angiogenesis.
It is used to treat various types of cancer, including colorectal, lung, brean, and kidney cancers, as well as certain eye conditions.
Bevacizumab works by blocking the growth of new blood vessels, which deprives the tumor of nutrients and oxygen, ultimately slowing or stopping tumor growth.
Researchers can use PubCompare.ai's powerful AI-driven protocol comparison tool to identify the most effective and reproducible Bevacizumab protocols from literature, preprints, and patents, streamlining their research and unlockig new possibilites.
It is used to treat various types of cancer, including colorectal, lung, brean, and kidney cancers, as well as certain eye conditions.
Bevacizumab works by blocking the growth of new blood vessels, which deprives the tumor of nutrients and oxygen, ultimately slowing or stopping tumor growth.
Researchers can use PubCompare.ai's powerful AI-driven protocol comparison tool to identify the most effective and reproducible Bevacizumab protocols from literature, preprints, and patents, streamlining their research and unlockig new possibilites.
Most cited protocols related to «Bevacizumab»
Axitinib
Bevacizumab
Ethics Committees, Research
Immunotherapy
Malignant Neoplasms
MTOR Inhibitors
Patients
pazopanib
Sorafenib
Sunitinib
Vascular Endothelial Growth Factors
Bevacizumab
Core Needle Biopsy
Docetaxel
Epirubicin
Fishes
Freezing
Immunohistochemistry
Inflammatory Breast Carcinoma
Lymph Node Metastasis
Malignant Neoplasm of Breast
Malignant Neoplasms
Neoplasms
Operative Surgical Procedures
Patients
Tissues
Triple Negative Breast Neoplasms
This prospective, consecutive, observational, noninterventional study included 113 patients with diagnosis of wet-type age-related macular degeneration (AMD) and diabetic macular edema (DME). None of the patients had known psychiatric conditions or used anxiolytic drugs. All subjects received intravitreal ranibizumab or bevacizumab injections performed by the same surgeon. To measure the level of anxiety, Spielberg's State-Trait Anxiety Inventory (STAI) questionnaire was used. All patients completed the questionnaire by themselves immediately before intravitreal injection.
STAI is the “gold standard” for measuring preoperative anxiety [2 , 3 (link), 4 (link)]. It comprises separate self-report scales for measuring two distinct anxiety concepts: state anxiety and trait anxiety. The reliability and validity of the STAI are well reported (Cronbach's alpha = 0.896). The STAI-T scale consists of 20 statements that ask people to describe how they generally feel. The STAI-S scale also consists of 20 statements, but the instructions require subjects to indicate how they feel at a particular moment in time. The STAI-S scale can be used to determine the actual levels of anxiety intensity induced by stressful procedures. The validity of the STAI rests upon the assumption that the examinee has a clear understanding of the “state” and “trait” instructions. Each question is rated on a 4-point scale (not at all, somewhat, moderately so, very much so). The range of possible scores for form Y of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-T and STAI-S subscales. STAI scores are commonly classified as “no or low anxiety” (20-37), “moderate anxiety” (38-44), and “high anxiety” (45-80). We used form Y of STAI in English and had it translated into Turkish by an expert in the respective languages. The translated forms were then retranslated back to English. The retranslated sentences which most closely resembled the original English STAI form Y sentences were used for that language.
SPSS, version 18 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Normality of the data was tested with a Kolmogorov-Smirnov test to indicate the appropriateness of parametric testing.
Values are presented as means ± standard deviation. A Mann-Whitney U test and Wilcoxon test were used for nonparametric data. Parametric data were analyzed using a Student t test. Pearson correlation and Spearman correlation tests were used to measure the linear association between two variables. A p value of less than 0.05 was considered to be statistically significant.
STAI is the “gold standard” for measuring preoperative anxiety [2 , 3 (link), 4 (link)]. It comprises separate self-report scales for measuring two distinct anxiety concepts: state anxiety and trait anxiety. The reliability and validity of the STAI are well reported (Cronbach's alpha = 0.896). The STAI-T scale consists of 20 statements that ask people to describe how they generally feel. The STAI-S scale also consists of 20 statements, but the instructions require subjects to indicate how they feel at a particular moment in time. The STAI-S scale can be used to determine the actual levels of anxiety intensity induced by stressful procedures. The validity of the STAI rests upon the assumption that the examinee has a clear understanding of the “state” and “trait” instructions. Each question is rated on a 4-point scale (not at all, somewhat, moderately so, very much so). The range of possible scores for form Y of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-T and STAI-S subscales. STAI scores are commonly classified as “no or low anxiety” (20-37), “moderate anxiety” (38-44), and “high anxiety” (45-80). We used form Y of STAI in English and had it translated into Turkish by an expert in the respective languages. The translated forms were then retranslated back to English. The retranslated sentences which most closely resembled the original English STAI form Y sentences were used for that language.
SPSS, version 18 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Normality of the data was tested with a Kolmogorov-Smirnov test to indicate the appropriateness of parametric testing.
Values are presented as means ± standard deviation. A Mann-Whitney U test and Wilcoxon test were used for nonparametric data. Parametric data were analyzed using a Student t test. Pearson correlation and Spearman correlation tests were used to measure the linear association between two variables. A p value of less than 0.05 was considered to be statistically significant.
Age-Related Macular Degeneration
Anxiety
Bevacizumab
Diagnosis
Edema, Macular
Feelings
Gold
Mental Disorders
Neuroses, Anxiety
Patients
Ranibizumab
REST protein, human
Self Concept
Student
Surgeons
Tranquilizing Agents
Base of Skull
Bevacizumab
Chemoradiotherapy
Cisplatin
Fluorouracil
Maxillary Sinus
Nasal Cavity
Nasopharynx
Neck
Necrosis
Nodes, Lymph
Pharmaceutical Adjuvants
Pharyngeal Space, Lateral
Pterygopalatine Fossa
Radiotherapy
Radiotherapy, Intensity-Modulated
Scan, CT PET
Sphenoid Sinus
Therapeutics
Veins
Age-Related Macular Degeneration
Bevacizumab
Choroidal Neovascularization
Eye
Lens, Crystalline
Ocular Refraction
Patients
Ranibizumab
Refractive Errors
Retina
Safety
Visual Acuity
Most recents protocols related to «Bevacizumab»
Example 3
Measurement of Dissociation Constant of KLHa505 and KLHb1501 for Binding to rhVEGF
With the use of BIAcore-3000, Kd of KLHa505 and Kd of KLHb1501 for binding to VEGF were determined. rhVEGF was immobilized on a CMS chip, serial dilution was performed twice with HBS-EP buffer, and then each antibody was injected at a flow rate of 30 μL/min. Kd is Koff/Kon.
As a result, it was demonstrated that the dissociation constant for binding of KLHa505 to rhVEGF was 4.23 pmol/L, and the dissociation constant for binding of KLHb1501 to rhVEGF was 0.60 pmol/L.
When compared with the dissociation constant for an existing antibody (for example, the dissociation constant for Avastin (bevacizumab) is 4.9 nmol/L), the dissociation constants for the antibodies of the present invention were each 1/1000 or less that for the existing antibody. Hence, the binding activity of the antibodies that bind to VEGF is significantly high.
That is, in this Example, the antibodies (high-affinity anti-VEGF antibodies) having extremely high affinity for VEGF were obtained.
Full text: Click here
Anti-Antibodies
Antibodies
Antibody Dissociation
Avastin
Bevacizumab
Buffers
DNA Chips
Immunoglobulins
Technique, Dilution
Vascular Endothelial Growth Factors
This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (Supplementary Checklist S1, Supplemental Digital Content, http://links.lww.com/MD/I616 ).[8 (link),9 (link)] Two investigators independently searched for studies published before October 31, 2022 in PubMed, Embase, Cochrane Library, and Web of Science. The search keywords were “immune checkpoint inhibitors, ‘PD1 inhibitors’, ‘PDL1 inhibitors’, ‘nivolumab’, ‘pembrolizumab’, ‘camrelizumab’, and ‘radiotherapy’, ‘Stereotactic body radiation therapy’, ‘SBRT’, and ‘angiogenesis inhibitors’, ‘bevacizumab’, ‘apatinib’, ‘sorafenib’, and,” “cancer,” “carcinoma,” “carcinoma,” “tumor”; the search strategy for each database is shown in Supplementary Table S1, Supplemental Digital Content, http://links.lww.com/MD/I617 . In addition, references to reviews and original studies were scanned to avoid missing studies that should be included.
Full text: Click here
Angiogenesis Inhibitors
apatinib
Bevacizumab
camrelizumab
Carcinoma
CD274 protein, human
cDNA Library
Human Body
Immune Checkpoint Inhibitors
inhibitors
Malignant Neoplasms
Neoplasms
Nivolumab
pembrolizumab
Programmed Cell Death Protein 1 Inhibitor
Radiosurgery, Stereotactic
Radiotherapy
Sorafenib
Information on which anti-VEGF medicine (ranibizumab, bevacizumab or aflibercept) was administered to each patient was obtained from the EPR, and the unit prices were obtained from the hospital pharmacy. The medicine costs for all patients were summed and divided by the number of injections to find the average medicine cost per injection. The equipment costs included the aggregated volume of disposable equipment at purchase price and the cost of cleaning reusable equipment, divided by the number of injections (Table 4 ).
Full text: Click here
aflibercept
Bevacizumab
Patients
Pharmaceutical Preparations
Ranibizumab
Vascular Endothelial Growth Factors
Patients with RAS and BRAF wt mCRC, treated with R or T versus anti-EGFR-based treatment in third-line, were retrospectively included in the study. Patients were enrolled by four Italian Medical Oncology Units (Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome; Ospedale Fatebenefratelli Isola Tiberina - Gemelli Isola, Rome; Department of Medical Oncology, Campus Bio-Medico University, Rome; Ospedale F. Spaziani - ASL Frosinone)
Patients had to have received two prior regimens of standard chemotherapy (oxaliplatin, irinotecan, fluoropyrimidine) for metastatic disease. Previous treatments could include bevacizumab. Patients who received cetuximab and/or panitumumab in first- or second-line were excluded from the anti-EGFR group; on the contrary, they could be enrolled in the R/T group. Prior therapy with R or T was not allowed.
The R-sided tumor was defined as cancer from the cecum to the transverse colon, L-sided tumor was defined as cancer from the splenic flexure to the rectum. For each patient we collected the following available variables: baseline ECOG performance status (PS), gender, age, synchronous vs metachronous disease, previous anticancer treatments, and number of metastatic sites (single vs multiple).
Patients had to have received two prior regimens of standard chemotherapy (oxaliplatin, irinotecan, fluoropyrimidine) for metastatic disease. Previous treatments could include bevacizumab. Patients who received cetuximab and/or panitumumab in first- or second-line were excluded from the anti-EGFR group; on the contrary, they could be enrolled in the R/T group. Prior therapy with R or T was not allowed.
The R-sided tumor was defined as cancer from the cecum to the transverse colon, L-sided tumor was defined as cancer from the splenic flexure to the rectum. For each patient we collected the following available variables: baseline ECOG performance status (PS), gender, age, synchronous vs metachronous disease, previous anticancer treatments, and number of metastatic sites (single vs multiple).
Full text: Click here
Bevacizumab
BRAF protein, human
Cecum
Cetuximab
EGFR protein, human
Electrocorticography
Gender
Irinotecan
Left Colic Flexure
Malignant Neoplasms
Neoplasms
Oxaliplatin
Panitumumab
Patients
Pharmacotherapy
Rectum
Transverse Colon
Treatment Protocols
This study was a retrospective consecutive case series of patients diagnosed with treatment-naïve unilateral CRVO between January 2010 and September 2017 at the Hangil Eye Hospital. The inclusion criteria for this study were as follows: (1) symptomatic CRVO in which retinal hemorrhage and retinal edema involved the macula, (2) foveal thickness greater than 300 μm as measured by OCT at initial visits, and (3) macular edema treated with intravitreal bevacizumab. An intravitreal injection of bevacizumab was administered in the same manner as reported previously28 (link). All patients were treated using a pro-re-nata regimen. The diagnosis of CRVO was based on the findings from fundus examination and fluorescein angiography. CRVO with a non-perfusion area larger than 10 disc areas on fluorescein angiography was defined as ischemic CRVO. Visual acuity improvement of 2 lines or more in the CRVO eyes following treatment was defined as a functional responder.
The exclusion criteria of the study included patients with any coexisting ocular diseases, such as age-related macular degeneration, diabetic retinopathy, and uveitis, as well as eyes that had received focal/grid laser photocoagulation, pan-retinal photocoagulation, prior intravitreal injections (e.g., intravitreal corticosteroids, intravitreal anti-VEGF agents), or prior ocular surgery (except cataract surgery). Patients were also excluded if they had refractive disorders greater than ± 3D.
Patient charts were reviewed for the following data: age, sex, medical history (hypertension and diabetes mellitus), best-corrected visual acuity (BCVA), axial length (measured with the IOL master; Carl Zeiss Meditec, Dublin, California, USA), anti-VEGF injection dates, and number of intravitreal injections. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR). The BCVA, IOP, and SFCT were compared between CRVO eyes and fellow eyes at each follow-up visit.
The exclusion criteria of the study included patients with any coexisting ocular diseases, such as age-related macular degeneration, diabetic retinopathy, and uveitis, as well as eyes that had received focal/grid laser photocoagulation, pan-retinal photocoagulation, prior intravitreal injections (e.g., intravitreal corticosteroids, intravitreal anti-VEGF agents), or prior ocular surgery (except cataract surgery). Patients were also excluded if they had refractive disorders greater than ± 3D.
Patient charts were reviewed for the following data: age, sex, medical history (hypertension and diabetes mellitus), best-corrected visual acuity (BCVA), axial length (measured with the IOL master; Carl Zeiss Meditec, Dublin, California, USA), anti-VEGF injection dates, and number of intravitreal injections. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR). The BCVA, IOP, and SFCT were compared between CRVO eyes and fellow eyes at each follow-up visit.
Full text: Click here
Adrenal Cortex Hormones
Age-Related Macular Degeneration
Anti-Anxiety Agents
Bevacizumab
Cataract Extraction
Diabetes Mellitus
Diabetic Retinopathy
Diagnosis
Edema, Macular
Eye
Fluorescein Angiography
High Blood Pressures
Light Coagulation
Macula Lutea
N-acetyltryptophanamide
Patients
Perfusion
Refractive Errors
Retina
Retinal Edema
Retinal Hemorrhage
Treatment Protocols
Uveitis
Vascular Endothelial Growth Factors
Vision
Visual Acuity
Top products related to «Bevacizumab»
Sourced in Switzerland, United States, Germany, France, China
Bevacizumab is a recombinant humanized monoclonal antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF).
Sourced in United States, Cameroon
Bevacizumab is a recombinant humanized monoclonal antibody that binds to and inhibits the biological activity of human vascular endothelial growth factor (VEGF).
Sourced in United States, Cameroon, United Kingdom
Avastin is a laboratory-produced monoclonal antibody used in various scientific research applications. It functions by targeting and binding to a specific protein involved in the process of angiogenesis, which is the formation of new blood vessels. Avastin's core function is to inhibit this process, but its precise application and intended use are not included in this response.
Sourced in Switzerland, Germany, United Kingdom, United States
Avastin is a laboratory product manufactured by Roche. It is a recombinant humanized monoclonal antibody designed to inhibit the vascular endothelial growth factor (VEGF) protein, which is involved in the formation of new blood vessels.
Sourced in United States, United Kingdom, Germany, China, Canada, Japan, Italy, France, Belgium, Australia, Uruguay, Switzerland, Israel, India, Spain, Denmark, Morocco, Austria, Brazil, Ireland, Netherlands, Montenegro, Poland
Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. It is widely used as a substrate for the in vitro cultivation of cells, particularly those that require a more physiologically relevant microenvironment for growth and differentiation.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States
Lucentis is an ophthalmic solution used for the treatment of various eye conditions. It contains the active ingredient ranibizumab, which is a recombinant humanized monoclonal antibody fragment. Lucentis is designed to inhibit vascular endothelial growth factor (VEGF) and reduce the growth of abnormal blood vessels in the eye.
Sourced in United States
Bevacizumab is a monoclonal antibody that binds to and inhibits the vascular endothelial growth factor (VEGF). It is used in the production and research of pharmaceuticals.
Sourced in United States, Switzerland
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the vascular endothelial growth factor (VEGF). It is designed for use in the treatment of various eye conditions.
Sourced in Switzerland, Germany, China
Ranibizumab is a biopharmaceutical product that functions as an anti-vascular endothelial growth factor (anti-VEGF) agent. It is a recombinant humanized monoclonal antibody fragment designed to bind to and inhibit the activity of human VEGF protein.
More about "Bevacizumab"
Bevacizumab, also known as Avastin, is a recombinant humanized monoclonal antibody that binds to and inhibits the vascular endothelial growth factor (VEGF), a critical regulator of angiogenesis.
This groundbreaking treatment has been approved for the management of various cancers, including colorectal, lung, breast, and kidney cancers, as well as certain eye conditions.
Bevacizumab works by blocking the growth of new blood vessels, depriving the tumor of essential nutrients and oxygen, ultimately slowing or stopping tumor growth.
This mechanism of action is known as anti-angiogenesis, and it has revolutionized the field of cancer therapy.
Researchers can leverage the power of PubCompare.ai's cutting-edge AI-driven protocol comparison tool to identify the most effective and reproducible Bevacizumab protocols from the vast body of literature, preprints, and patents.
This innovative platform allows for side-by-side comparison of multiple protocols, enabling researchers to streamline their studies and unlock new possibilities in Bevacizumab-related research.
In addition to Bevacizumab and Avastin, other related terms and concepts include Matrigel, a commonly used extracellular matrix substrate for cell culture and angiogenesis assays, and FBS (Fetal Bovine Serum), a crucial component in cell culture media.
Lucentis (Ranibizumab) is another anti-VEGF therapy, similar in mechanism to Bevacizumab, that has been approved for the treatment of certain eye conditions.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their Bevacizumab studies, leading to more effective treatments and improved patient outcomes.
The platform's intuitive interface and cutting-edge analysis capabilities empower researchers to navigate the complex landscape of Bevacizumab research with ease and efficiency.
This groundbreaking treatment has been approved for the management of various cancers, including colorectal, lung, breast, and kidney cancers, as well as certain eye conditions.
Bevacizumab works by blocking the growth of new blood vessels, depriving the tumor of essential nutrients and oxygen, ultimately slowing or stopping tumor growth.
This mechanism of action is known as anti-angiogenesis, and it has revolutionized the field of cancer therapy.
Researchers can leverage the power of PubCompare.ai's cutting-edge AI-driven protocol comparison tool to identify the most effective and reproducible Bevacizumab protocols from the vast body of literature, preprints, and patents.
This innovative platform allows for side-by-side comparison of multiple protocols, enabling researchers to streamline their studies and unlock new possibilities in Bevacizumab-related research.
In addition to Bevacizumab and Avastin, other related terms and concepts include Matrigel, a commonly used extracellular matrix substrate for cell culture and angiogenesis assays, and FBS (Fetal Bovine Serum), a crucial component in cell culture media.
Lucentis (Ranibizumab) is another anti-VEGF therapy, similar in mechanism to Bevacizumab, that has been approved for the treatment of certain eye conditions.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their Bevacizumab studies, leading to more effective treatments and improved patient outcomes.
The platform's intuitive interface and cutting-edge analysis capabilities empower researchers to navigate the complex landscape of Bevacizumab research with ease and efficiency.